Merck Research Laboratories, along with many other pharmaceutical giants, would love to be able to hit the market with real HGH in pill form, as opposed to HGH “releaser”supplements which are freely available and don’t fall under FDA jurisdiction.
So it was some excitement that beginning in 2008, researchers at the University of Virginia conducted a two-year study of 65 healthy older adults, giving some an oral ghrelin mimetic, or MK-677, and others a placebo.
They discovered that participants between 60 and 81 who received MK-677, a drug provided by Merck Research Laboratories, experienced increased growth hormone levels to those seen in young adults.
Michael Thorner, MB, BS, DSc, and Ralf Nass, MD, of the University of Virginia, reported that that blood sugar increased in people taking the new drug, and the body’s sensitivity to insulin decreased slightly.
Unfortunately, according to Thorner,”The changes are very mild and are unlikely to be of clinical significance in subjects who are not diabetic.”
The purpose of the study, as published in the publication “Annals of Internal Medicine”, was to determine whether stimulating growth hormone altered body composition. According to the researchers, it did.
It was reported that the subjects gained muscle mass, body weight (without body fart gain) and enhanced appetite. There were no significant side-effects.
This project was funded by the National Institutes of Health, but because the test group was so small, researchers caution actula time to market for the pill could be years away, to allow time for tests on larger groups.